Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Exscientia, the leading AI Drug Discovery company, has today announced its collaboration with the Alzheimer’s Research UK Oxford Drug Discovery Institute (ARUK-ODDI) to develop medicines targeting neuroinflammation for the treatment of Alzheimer’s disease (AD).

brain

AD is the most common form of dementia worldwide, with an estimated 44 million people living with AD or related form of dementia [1]. Symptoms of this progressive disease are debilitating, distressing – for both those with the disease and their loved ones –and there is currently no cure [3].

This exciting new partnership unites Exscientia's AI-driven molecular design capabilities with the deep therapy area knowledge and technical expertise of the ARUK-ODDI.

The collaboration will focus on a specific neuroinflammatory pathway implicated in the development of AD. Activation of the NLRP3 inflammasome has been shown to have an important role in AD pathogenesis and, while there have been other efforts to develop anti-inflammatory drugs for AD [4], targeting NLRP3 inflammasome inhibition in the brain is an innovative therapeutic approach.

Exscientia’s proven AI-driven technology will be applied to efficiently generate high-value novel clinical assets targeting this pathway. Feeding into this are chemical starting points that modulate NLRP3 inflammasome formation identified over years of research by the ARUK-ODDI. Coupling Exscientia's Centaur Chemist® AI-design systems with the ARUK-ODDI’s biology and screening expertise is expected to speed up delivery of distinct candidate molecules for AD.

Exscientia’s COO David Hallett commented: “Alzheimer’s is a dreadful disease that affects tens of millions worldwide. Despite clinical trials of numerous agents over a wide range of mechanisms, the last new Alzheimer’s medication, was approved nearly two decades ago. Alzheimer’s drug development is costly, complex and extremely challenging with clinical trial failure rate being the highest of any therapeutic area. Our mission is to make safer, more effective drugs available to all and we are excited to utilise our AI drug discovery platform and work alongside the expertise of the Alzheimer’s Research UK-Oxford Drug Discovery Institute team to accelerate innovation and develop potential medicines to solve this global epidemic.”  

Expanding on this new relationship, Prof John Davis, CSO of the Alzheimer’s Research UK-Oxford Drug Discovery Institute drew attention to the benefits gained from the complementary capabilities of both partners: "We are delighted to be partnering with Exscientia. Their state-of-the-art AI capabilities will enable us to investigate multiple molecules in parallel and accelerate the project towards candidate declaration.  Human genetic variation points towards a critical role for the body’s immune system in an individual’s risk of developing Alzheimer’s disease.  It is vital that we develop treatments that target neuroinflammatory mechanisms underlying dementia.”

Dr Sara Imarisio, Head of Research at Alzheimer’s Research UK said:
“Scientist’s at our ARUK-Oxford Drug Discovery Institute are ideally placed to capitalise on the latest discoveries and work with partners to help translate this into drugs that could be tested in clinical trials. With nearly one million people in the UK living with dementia, there isn’t a moment to waste.”

References

[1] World Health Organization. Fact Sheet. Dementia. Accessed 28 January 2021

[2] Alzheimer’s News Today. Accessed 28 January 2021

[3] NHS. Alzheimer’s Disease. Accessed 28 January 2021

[4] Immunity’s flipside: Microglia promote Alzheimer’s pathology during inflammation. Accessed 28 January 2021

 

Similar stories

National survey reveals big reductions in COVID-19 infections with single dose of Oxford-AZ and Pfizer vaccines

News

Data from the national COVID-19 Infection Survey, which is led by senior NIHR Oxford BRC researcher Professor Sarah Walker, has revealed the impact of vaccination on antibody responses and new infections in a large group of adults from the general population. This major community surveillance survey, one of the NIHR’s COVID-19 urgent public health studies, is a partnership between the University of Oxford, the Office of National Statistics (ONS) and the Department for Health and Social Care (DHSC).

CCOUC Webinar on Health-EDRM Education and Research in China: Commemorating the 512 Wenchuan Earthquake

News

You are cordially invited to join the CCOUC Webinar on Health-EDRM Education and Research in China: Commemorating the 512 Wenchuan Earthquake. As a commemoration of the 512 Wenchuan Earthquake in 2008, experts will share with you an update on the latest Health-EDRM Education and Research in China. This is a webinar of the CCOUC 10th Anniversary International Webinar Series on Health Emergency and Disaster Risk Management.

Oxford University researchers release cheap, quick COVID-19 antibody test

News

The new easy-to-produce test detects coronavirus spike-protein binding antibodies in people who have tested positive for COVID-19.

The RECOVERY Trial: One year on

News

Thanks to the ground-breaking work of RECOVERY, clinicians treating patients hospitalised with severe COVID-19 now have two treatments that are known to improve survival. From having no known effective drugs when the pandemic first erupted, patients are now offered treatments that have been robustly proven to reduce death and improve other outcomes, such as the length of hospital stay and the need for mechanical ventilation.

USA, Chile and Peru interim trial data show Oxford-AstraZeneca vaccine is safe and highly effective

News

A Phase III study of the Oxford-AstraZeneca coronavirus vaccine conducted by AstraZeneca plc in the USA, Chile and Peru has shown that vaccine is safe and highly effective, adding to previous trial data from the United Kingdom, Brazil and South Africa, as well as real-world impact data from the United Kingdom.

Professor Cecilia Lindgren appointed Director of the Big Data Institute

News

Professor Cecilia Lindgren has been appointed as the new Director of the University of Oxford’s Big Data Institute. Professor Lindgren will take up post on 1 April 2021. She succeeds Professor Gil McVean who was the founding director of the BDI, and Interim Director, Professor Martin Landray.